GSK acquires oligonucleotide drug startup Elsie
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
The facility will accommodate over 1,500 employees
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Subscribe To Our Newsletter & Stay Updated